Journal Article

Senolytic treatment diminishes microglia and decreases severity of experimental autoimmune encephalomyelitis

Hua, Elizabeth M.-L., Fournier, Alyson E., Klement, Wendy, Prat, Alexandre, Zandee, Stephanie, Zaman, Aliyah, Gianfelice, Christine, Afanasiev, Elia, Drake, Sienna S., Heale, Kali, Stratton, Jo Anne

2024

Overview

Background The role of senescence in disease contexts is complex, however there is considerable evidence that depletion of senescent cells improves outcomes in a variety of contexts particularly related to aging, cognition, and neurodegeneration. Much research has shown previously that inflammation can promote cellular senescence. Microglia are a central nervous system innate immune cell that undergo senescence with aging and during neurodegeneration. The contribution of senescent microglia to multiple sclerosis, an inflammatory neurodegenerative disease, is not clear, but microglia are strongly implicated in chronic active lesion pathology, tissue injury, and disease progression. Drugs that could specifically eliminate dysregulated microglia in multiple sclerosis are therefore of great interest to the field. Results A single-cell analysis of brain tissue from mice subjected to experimental autoimmune encephalomyelitis (EAE), a mouse model of CNS inflammation that models aspects of multiple sclerosis (MS), identified microglia with a strong transcriptional signature of senescence including the presence of BCL2-family gene transcripts. Microglia expressing Bcl2l1 had higher expression of pro-inflammatory and senescence associated genes than their Bcl2l1 negative counterparts in EAE, suggesting they may exacerbate inflammation. Notably, in human single-nucleus sequencing from MS, BCL2L1 positive microglia were enriched in lesions with active inflammatory pathology, and likewise demonstrated increased expression of immune genes suggesting they may be proinflammatory and contribute to disease processes in chronic active lesions. Employing a small molecule BCL2-family inhibitor, Navitoclax (ABT-263), significantly reduced the presence of microglia and macrophages in the EAE spinal cord, suggesting that these cells can be targeted by senolytic treatment. ABT-263 treatment had a profound effect on EAE mice: decreasing motor symptom severity, improving visual acuity, promoting neuronal survival, and decreasing white matter inflammation. Conclusion These results support the hypothesis that microglia and macrophages exhibit transcriptional features of cellular senescence in EAE and MS, and that microglia expressing Bcl2l1 demonstrate a proinflammatory signature that may exacerbate inflammation resulting in negative outcomes in neuroinflammatory disease. Depleting microglia and macrophages using a senolytic results in robust improvement in EAE disease severity, including across measures of neurodegeneration, inflammation, and demyelination, and may therefore represent a novel strategy to address disease progression in multiple sclerosis.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Aniline Compounds - pharmacology / Aniline Compounds - therapeutic use / Animals / Biomedical and Life Sciences / Biomedicine / Care and treatment / Cellular Senescence - drug effects / Development and progression / Diagnosis / Encephalomyelitis / Encephalomyelitis, Autoimmune, Experimental - drug therapy / Encephalomyelitis, Autoimmune, Experimental - pathology / Experimental autoimmune encephalomyelitis / Female / Health aspects / Humans / Immunology / Macrophages / Mice / Mice, Inbred C57BL / Microglia / Microglia - drug effects / Microglia - metabolism / Microglia - pathology / Multiple sclerosis / Neurobiology / Neuroinflammation / Neurology / Neurosciences / Senescence / Senolytics / Senotherapeutics - pharmacology / Senotherapeutics - therapeutic use / Sulfonamides - pharmacology / Sulfonamides - therapeutic use